Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.73)
# 144
Out of 5,106 analysts
47
Total ratings
65.96%
Success rate
36.14%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Maintains: Buy | $54 → $64 | $47.06 | +36.00% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $35.56 | -4.39% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.55 | +85.43% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.92 | +231.63% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $7.17 | +53.42% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $9.39 | +17.15% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.01 | -0.33% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.65 | +164.15% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $14.56 | +16.76% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $16.71 | +67.56% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $19.05 | +104.72% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $3.58 | +123.46% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.37 | +102.51% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $5.77 | +3.99% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $7.23 | +65.98% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $7.72 | +29.53% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $21.36 | +7.68% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.73 | +65.52% | 2 | Jul 11, 2023 |
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $47.06
Upside: +36.00%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $35.56
Upside: -4.39%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.55
Upside: +85.43%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.92
Upside: +231.63%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $7.17
Upside: +53.42%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $9.39
Upside: +17.15%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.01
Upside: -0.33%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.65
Upside: +164.15%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $14.56
Upside: +16.76%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $16.71
Upside: +67.56%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $19.05
Upside: +104.72%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.58
Upside: +123.46%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.37
Upside: +102.51%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $5.77
Upside: +3.99%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $7.23
Upside: +65.98%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $7.72
Upside: +29.53%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $21.36
Upside: +7.68%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.73
Upside: +65.52%